One Focus

What it is A structured competitive intelligence programme that brings clarity, focus, and decision discipline at the pre-proof of concept stage. For early-stage asset teams and pipeline leaders, the critical challenge is making high-stakes investment and prioritisation decisions when scientific promise is high but competitive and commercial uncertainty is extreme. We separate signal from noise to surface the few insights that should drive early go/no-go and prioritisation decisions.

When clients use this

• Pre-PoC decisions for pipeline assets or target validation
• Portfolio prioritisation and go/no-go commercial milestones
• Before meaningful investment, partnering, or trial design commitments

Why Eradigm is different

• Focused on decisions, not exhaustive landscapes
• Designed for uncertainty: scenarios and signposts, not predictions
• Light-touch, hypothesis-driven CI that evolves with the programme

What clients receive Three flexible engagement models, from strategic sprints to light-touch ongoing support:

1. Opportunity Assessment — a clear, evidence-based view on whether an asset is worth backing, where differentiation may be credible, and what must be true for the programme to justify investment.
2. Scenario Planning — a structured set of plausible future states for the competitive space, enabling teams to anticipate risks, identify breakpoints, and align on strategic options before choices harden.
3. Light-Touch Monitoring — a focused early-warning system that continuously filters signal from noise, flagging only the developments that materially change assumptions, strategy, or prioritisation.

By the numbers 30+ early-CI projects delivered | 40+ assets assessed pre-PoC | 4.6/5 client satisfaction | Typical project duration 8–12 weeks

Client voice “Eradigm didn’t just outline possible futures — they helped us align cross-functionally on what we would actually do in each one.”  New Product Planning Lead, global immunology team

What it is Continuous, tailored monitoring programmes that run across the full product lifecycle, often spanning multi-year engagements with strong renewals. Brand teams and TA leads must compete in complex, dynamic global markets where understanding and anticipating competitive catalysts are key to reducing uncertainty at every stage. We empower CI teams to directly support these key decision-makers — providing the clarity needed to fuel smarter conversations and more confident decisions.

When clients use this

• Real-time intelligence on competitive news, with full context and “why it matters” implications
• True thought-partnership, providing CI support through a strategic lens
• Holistic understanding of the landscape through news monitoring, conference coverage, and deep dives

Why Eradigm is different

• Thoughtful AI and tech integration to expand coverage and accelerate delivery, elevating insight quality rather than replacing human judgement
• The right level of information to trigger internal dialogue and decision-making — not noise, not silence
• Tailored CI programmes designed around individual client needs, not off-the-shelf templates
• Consultants focus on implications and decision triggers, not manual signal filtering

What clients receive

1. Pre-Launch Support — monitoring of the current and near-term competitive landscape, with targeted deep dives providing intelligence on competitor success factors, launch sequencing, marketing, and patient engagement models.
2. Marketed Asset and Franchise — comprehensive and continuous analysis of the competitive space, with threats and opportunities distilled into actionable insights for both brand and TA leads.
3. Lifecycle Management — early identification of catalysts and new market entrants, with targeted deep dives and competitive workshops to understand relative threat and maximise product market share.

Ongoing deliverables typically include alerts and FYI monitoring, regularly refreshed clinical trial trackers, competitor asset cards, launch timelines, brand decks, catalyst trackers, congress coverage, readout presentations, and ad-hoc deep-dive support.

By the numbers 100+ monitoring programmes delivered | 1,500+ assets monitored from PoC to LCM |  Several partnerships continuing >5+ years | 4.7/5 client satisfaction

Client voice “Our remit is so large and complex with stakeholders in constant need of CI support; Eradigm not only delivered with quality and responsiveness, but helped us shape our deliverables and processes internally.” Strategy and Insights Director, major infectious disease franchise

What it is CI at the organisational level. An under-leveraged opportunity to utilise competitive intelligence to align cross-functional leaders and unlock broader organisational value. Enterprise strategy leaders face a rapidly evolving landscape where digital transformation, policy shifts, and AI adoption are becoming critical, making it essential to use CI proactively to predict trends and stay ahead of the competitive curve. Our enterprise expertise brings CI into new strategic forums, expanding its influence and accelerating business-wide impact.

When clients use this

• Spotting and tracking pharma trends and forecasting competitive inflection points
• Organisational benchmarking from R&D to policy to AI transformation
• Supporting the development, rollout, and implementation of enterprise CI tools and processes

Why Eradigm is different

• Transparent framework — clear scoring logic and source trails so teams can challenge, align, and trust the output
• Above-brand but client-grounded: trend outlook stays enterprise-level while explicitly tying back to the client’s specific context
• Decision-ready outputs built for the next governance milestone, not abstract reports

What clients receive

1. Competitor Benchmarking — enterprise deep-dives that support cross-functional stakeholders to identify gaps and build upon existing differentiation versus peers, accelerating and enhancing transformation.
2. Megatrends Monitoring — monitoring and materials on emerging trends that allow CI teams to react instantly when stakeholder questions surface, and proactively identify where to dig deeper.
3. Enterprise Conference Coverage — attendance of enterprise-level pharma conferences places clients at the centre of innovation, gaining insights that support strategy transformation across the value chain, rarely covered by traditional CI providers.

By the numbers 30+ enterprise projects completed | 9/10 reported client satisfaction | 4.5/5 client thought-partnership rating | 10 AI transformation-related deep-dives delivered

Client voice “Everyone could see the trend scoring logic and challenge it, which helped us align fast. You kept the outlook at enterprise-level but still anchored it in our context, and you turned it into decision-ready insights.” — Enterprise CI Lead, Market Intelligence, top-5 pharma

View Case Study

What it is Conference coverage represents a golden opportunity for high-quality primary research, acting as both a complement to monitoring programmes and Eradigm’s closest connection to clients and competitors on the ground. For CI leaders, the challenge is ensuring comprehensive, accurate, and impactful analysis of conference data that can be rapidly cascaded to cross-functional stakeholders. We guarantee delivery of all conference components, so no insight is missed and no question goes unanswered.

When clients use this

• The first look at new and impactful competitor data releases
• Access to the right competitor and HCP sources for targeted primary research
• Analysis of competitor messaging, presence, and differentiation across pipeline and launched players

Why Eradigm is different

• Surgical focus on what’s new, not bloated post-conference reports
• Tailored and co-created Key Intelligence Questions; no vague or all-purpose briefs
• Deep commercial analysis, not a laundry list of messaging

What clients receive

1. Data Readout Coverage — rapid capture and synthesis of competitor clinical readouts in priority indications and mechanisms of action, translating key efficacy and safety signals into clear implications for differentiation, indication choice, and trial design.
2. Competitor Presence — assessment of competitor visibility and momentum through booth presence, attendee traffic, engagement levels, and overall share of voice beyond formal presentations.
3. On-the-Ground Primary Research — insights from KOLs and competitor conversations on site, capturing sentiment, perceptions of new data, and strategic shifts to complement secondary coverage with sharper interpretation.

By the numbers 50+ conferences attended per year |  | 9 major therapeutic areas covered | 10,000+ conference sessions covered

Client voice “The primary insights were the difference-maker. You captured how leaders were reacting in the moment, then translated it into clear implications for our therapy and diagnostics priorities while the congress was still live.” — CI Senior Manager, neurology team, top-5 pharma

View Case Study

What it is Hypothesis-driven primary intelligence that clarifies competitor direction, pressure-tests strategic assumptions, and highlights the signals that truly matter for decision-making. For pharma and biotech CI teams, the challenge is maintaining a clear, current view of competitor intent and strategy in environments where public information is incomplete, lagging, or deliberately ambiguous. We use targeted primary intelligence to surface what secondary research simply cannot reach.

When clients use this

• Ongoing asset, franchise, or TA-level monitoring, or ad-hoc intelligence needs
• Before key strategic decisions, i.e. conferences, data releases, strategic announcements
• To pressure-test assumptions and inform internal decision-making

Why Eradigm is different

• Primary-led and hypothesis-driven, insight is actively tested, not passively collected
• Focused on intent and implications, not activity tracking or exhaustive landscapes
• Built for decisions, triangulated insights with explicit impact on choices and priorities

What clients receive

A structured three-stage methodology:

1. Alignment and Hypothesis Framing — we work closely with CI and cross-functional stakeholders to align on Key Intelligence Questions and underlying hypotheses, ensuring primary intelligence is tightly scoped, decision-led, and relevant.
2. Targeted Primary Intelligence Collection — carefully selected, high-confidence sources across clinical, commercial, access, and industry roles. Conversations are hypothesis-driven, compliant, and designed to uncover competitor strategy.
3. Synthesis, Triangulation, and Implications — insights are triangulated across sources, contextualised with secondary evidence, and synthesised into clear implications and recommendations that directly inform strategic decisions and prioritisation.

By the numbers 200+ primary CI projects delivered | 4.7/5 client satisfaction | Global market reach including US, EU, APAC, and ROW

Client voice “The interviews surfaced a few blind spots for us. It made our assumptions tangible and we left with a clearer view of what needs to be true, and what we should adjust.” — VP Portfolio Strategy, cell and gene therapy company

View Case Study

What it is Structured working sessions that bring cross-functional teams to clear, aligned decisions on competitive implications and strategic direction. For cross-functional teams, the challenge is achieving rapid alignment on priorities when evidence may be incomplete, perspectives differ, and stakes are high. We bring teams to clear, aligned decisions and action plans, positioning Eradigm as a strategic partner, not just a CI provider.

When clients use this

• At key inflection points to align stakeholders on competitive implications and strategic response
• To resolve strategic ambiguity where evidence is incomplete, assumptions conflict, or ownership is unclear
• To accelerate decision-making by translating complex inputs into a clear, decision-ready direction

Why Eradigm is different

• Built to drive alignment, not facilitate open-ended discussion
• Structured to test assumptions and explore alternative scenarios
• Focused pre-work and structured sessions translate directly into clear implications and agreed next steps

What clients receive

1. H2H Competitor Simulation — simulates a head-to-head competitor move to sharpen your response: what you protect, what you change, and which new levers you pull as a newcomer enters across messaging, channels, access, and evidence.
2. Team Round Tables — brings together shared expertise across regions to compare what’s working, flag risks early, and agree priority opportunities, ending with a clear set of watchouts and next steps by team and region.
3. Pre-Launch Readiness — builds a robust launch playbook so teams know what to say, to whom, and when, with clear owners, defined timing, and a practical framework for handling objections and building share of voice.

By the numbers 50+ workshops delivered | 900+ total attendees across global and local teams spanning CI, medical, market access, and commercial | 9/10 client satisfaction via net promoter score

Client voice “The way you set up the discussions forced us to challenge ourselves, and the way you not only captured the essence of the conversations but became active members of the discussion was tremendous.” — CI Lead, Rare Diseases, major immunology company

View Case Study